As companies continue to collaborate and share their expertise to develop therapeutics targeting a wide range of diseases, European Pharmaceutical Review explores the aims of the most recent partnerships.
List view / Grid view
Otsuka Pharmaceutical Co. Ltd (Otsuka)
Filter the results
The FDA has approved the first drug in the U.S. with a digital ingestion tracking system that records that the medication was taken...
16 July 2015 | By Victoria White
Data from a post-hoc subset analysis of Phase IIb clinical trials suggests the potential efficacy of Otsuka’s delamanid for the treatment of XDR-TB...
24 June 2015 | By Victoria White
Otsuka and Lundbeck have announced newly released subgroup analysis of data from the QUALIFY study of Abilify Maintena (aripiprazole once-monthly)...
Otsuka’s JINARC (tolvaptan) becomes first-ever treatment approved in Europe for adults living with ADPKD
27 May 2015 | By Victoria White
The EC has granted marketing authorisation for tolvaptan for the treatment of ADPKD in adults who have chronic kidney disease (CKD)...
CHMP recommends JINARC® (tolvaptan) for approval in EU for treatment of autosomal dominant polycystic kidney disease
2 March 2015 | By Otsuka Pharmaceutical Co. Ltd
Otsuka Pharmaceutical Co., Ltd. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended JINARC® (tolvaptan) for approval...
Otsuka and Lundbeck´s brexpiprazole demonstrates statistically significant effects in New Phase III Studies in adult patients with schizophrenia
11 December 2014 | By H. Lundbeck A/S
... presented at the American College of Neuropsychopharmacology annual meeting.
Treatment with once-monthly Abilify Maintena® (aripiprazole) significantly reduces hospitalisation rates for patients with schizophrenia compared with daily oral antipsychotics
7 April 2014 | By Lundbeck
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Europe Ltd. (Otsuka) announced results from the final analysis of a mirror-image study showing statistically significant reductions (p
Lundbeck and Otsuka initiate European launch of Abilify Maintena®, a once-monthly formulation for the treatment of schizophrenia
18 March 2014 | By Lundbeck
Denmark is the first country in Europe where Abilify Maintena® is fully reimbursed and accessible to people diagnosed with schizophrenia...
Results of clinical phase III study of once-monthly aripiprazole IM depot formulation for the treatment of schizophrenia presented at APA
7 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced results from a clinical phase III clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia. Trial results were presented in four poster presentations at…
NDA for aripiprazole depot formulation for maintenance treatment of adult patients with schizophrenia accepted
22 November 2011 | By H. Lundbeck A/S (Lundbeck)
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today that the US Food and Drug Administration (FDA) has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit…
Lundbeck and Otsuka Pharmaceutical sign historic agreement to deliver innovative medicines targeting psychiatric disorders worldwide
11 November 2011 | By H. Lundbeck A/S (Lundbeck)
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced a development and commercialisation agreement for up to five products in the psychiatry field, including aripiprazole depot formulation and OPC-34712 from Otsuka and up to three highly innovative earlier stage projects from Lundbeck.